Technologies

AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).

Leishmaniasis is a zoonosis caused by the protozoan of the genus Leishmania, which affects both humans and animals through a phlebotomist. After malaria and lymphatic filariasis, leishmaniasis is the third most common disease on a global scale. Leishmania infantum is the species spread in the European continent and the Mediterranean basin. In Italy, from the hilly coastal areas and major islands, the infection has spread to many pre-Alpine areas and northern Italy.

This innovative technology involves the use of a high-affinity, highly specific antibody that targets extracellular domains of connexin hemichannels (Cx26, Cx30, and Cx32). The antibody has been designed to reduce or inhibit the growth of brain tumors, particularly glioblastoma (GBM), and to alleviate the associated epilepsy. By blocking connexin hemichannels, the antibody interferes with pathological ATP release and other signaling mechanisms that contribute to tumor progression and neural hyperexcitability.

The development of genome editing tools has revolutionized the way we think and deal with genetics. The use of Cas9 or its variants allows modifications of specific sites in the human genome by inducing deletions and insertions in a more or less controlled way. In recent years, a new class of tools for genome editing has emerged: the base editors (BE), which result from the fusion of a modified Cas9, which serves to direct the BE to the target, and an active deaminase acting on the DNA, which mediates the C> T or A> G editing.

Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.

The technology we participate to develop, called "Zinc-Finger Artificial Transcription Factors (ZF-ATFs)", allows to design, realize and select artificial genes coding for proteins capable of recognizing and binding "potentially" any DNA sequence. We used ZF-ATF technology to reprogram the expression of "beneficial" genes capable of efficiently counteracting the negative effect of mutated genes related to rare diseases.

Time-correlated single photon counting (TCSPC) is regarded as the “gold-standard” method for fluorescence lifetime measurements. However, TCSPC requires using highly sensitive detectors, not suitable for measurements under bright light conditions, thereby making the use impractical in clinical settings. The invention described here solves this problem by synchronizing the fluorescence detection with an external light source.

The Biocrystal Facility, a large multidisciplinary laboratory established at the Institute of Molecular Biology and Pathology (IBPM) of CNR, in collaboration with the Biochemistry Department of Sapienza University aims at supporting the italian scientists and the pharmaceutical companies in the research to find new drug and vaccine against the endemic and epidemic diseases through structure-based drug design.

The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms.

C-ImmSim is one of the most advanced computational models of the immune system. The software resorts to (bit or amino acid) strings to represent the “binding site” of cells and molecules. C-ImmSim is an agent-based model that includes the major classes of immune cells of the lymphoid lineage and some of the myeloid lineage. Helper T cells are divided into five phenotypes. B cells and plasma B are also divided into two phenotypes.

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

Health360 is a software framework for building cloud platforms to monitor the health of subjects recruited in clinical trials, residents of social housing or athletes in sports teams. The framework is based on interconnected and configurable modules to implement platforms that meet specific needs while maintaining a high level of usability.

The platform HistoPlat implies the development and validation of a mathematical algorithm, potentially combinable with an image analysis software, that, through a multiparametric approach including the immunohistochemical analysis of both expression and localization of multiple markers, allows the histopathologist or oncologist to optimize the diagnosis and prognosis, and to predict the clinical response to therapies directed towards validated and/or innovative molecular targets, also taking into account the individual variability of each pati

The herein described technology aims at the development of a platform of injectable hydrogels for application as drug carriers for localized delivery or in the regenerative medicine field. The use of ad-hoc synthesized poly(ether urethane)s (PEUs) as hydrogel forming materials is a common property which characterizes all the systems belonging to this platform.

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.